SEC Info - Kraig Biocraft Laboratories, Inc - ‘S-1’ on 6/2/20

SEC Info℠

Home

My Interests

Help

Please Sign In

Kraig Biocraft Laboratories, Inc – ‘S-1’ on 6/2/20 – ‘EX-101.CAL’

On: Tuesday, 6/2/20, at 4:47pm ET · Accession #: 1493152-20-10402 · File #: 333-238883

Previous ‘S-1’: ‘S-1/A’ on 6/2/15 · Next: ‘S-1/A’ on 8/24/20 · Latest: ‘S-1/A’ on 11/22/23 · 22 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/02/20  Kraig Biocraft Laboratories, Inc  S-1                   71:7.9M                                   M2 Compliance/FA

Registration Statement (General Form) — Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Registration Statement (General Form)               HTML   1.20M 
 2: EX-14.2     Code of Ethics                                      HTML     72K 
 3: EX-23.1     Consent of Experts or Counsel                       HTML     21K 
 4: EX-99.1     Miscellaneous Exhibit                               HTML     61K 
 5: EX-99.2     Miscellaneous Exhibit                               HTML     47K 
 6: EX-99.3     Miscellaneous Exhibit                               HTML     42K 
14: R1          Document Entity Information                         HTML     34K 
48: R2          Condensed Consolidated Balance Sheets               HTML    120K 
58: R3          Condensed Consolidated Balance Sheets               HTML     49K 
                (Parenthetical)                                                  
31: R4          Condensed Consolidated Statements of Operations     HTML     89K 
15: R5          Condensed Consolidated Statement of Changes in      HTML     79K 
                Stockholders Deficit                                             
49: R6          Condensed Consolidated Statement of Changes in      HTML     25K 
                Stockholders Deficit (Parenthetical)                             
59: R7          Condensed Consolidated Statements of Cash Flows     HTML    110K 
32: R8          Summary of Significant Accounting Policies and      HTML    114K 
                Organization                                                     
13: R9          Going Concern                                       HTML     28K 
37: R10         Equipment                                           HTML     35K 
20: R11         Right to Use Assets and Lease Liability             HTML     56K 
50: R12         Accrued Interest - Related Party                    HTML     32K 
60: R13         Note Payable                                        HTML     28K 
38: R14         Stockholders' Deficit                               HTML    157K 
21: R15         Commitments and Contingencies                       HTML     81K 
51: R16         Related Party Transactions                          HTML     63K 
61: R17         Subsequent Events                                   HTML     29K 
39: R18         Summary of Significant Accounting Policies and      HTML    153K 
                Organization (Policies)                                          
19: R19         Summary of Significant Accounting Policies and      HTML     62K 
                Organization (Tables)                                            
41: R20         Equipment (Tables)                                  HTML     33K 
66: R21         Right to Use Assets and Lease Liability (Tables)    HTML     40K 
26: R22         Stockholders' Deficit (Tables)                      HTML    145K 
22: R23         Summary of Significant Accounting Policies and      HTML     49K 
                Organization (Details Narrative)                                 
42: R24         Summary of Significant Accounting Policies and      HTML     43K 
                Organization (Details Narrative) (10-K)                          
67: R25         Summary of Significant Accounting Policies and      HTML     30K 
                Organization - Schedule of Antidilutive Securities               
                of Earnings Per Share (Details)                                  
27: R26         Summary of Significant Accounting Policies and      HTML     28K 
                Organization - Schedule of Antidilutive Securities               
                of Earnings Per Share (Details) (Parenthetical)                  
23: R27         Summary of Significant Accounting Policies and      HTML     35K 
                Organization - Schedule of Deferred Tax Assets and               
                Liabilities (Details) (10-K)                                     
40: R28         Summary of Significant Accounting Policies and      HTML     24K 
                Organization - Schedule of Deferred Tax Assets and               
                Liabilities (Details) (10-K) (Parenthetical)                     
68: R29         Summary of Significant Accounting Policies and      HTML     31K 
                Organization - Schedule of Components of Deferred                
                Income Taxes (Details) (10-K)                                    
64: R30         Summary of Significant Accounting Policies and      HTML     28K 
                Organization - Schedule of Fair Value of Financial               
                Instruments (Details)                                            
54: R31         Summary of Significant Accounting Policies and      HTML     34K 
                Organization - Schedule of Concentration of Credit               
                Risk (Details) (10-K)                                            
18: R32         Going Concern (Details Narrative)                   HTML     33K 
36: R33         Going Concern (Details Narrative) (10-K)            HTML     33K 
63: R34         Equipment (Details Narrative)                       HTML     25K 
53: R35         Equipment (Details Narrative) (10-K)                HTML     25K 
17: R36         Equipment - Schedule of Property and Equipment      HTML     37K 
                (Details)                                                        
35: R37         Right to Use Assets and Lease Liability - (Details  HTML     59K 
                Narrative)                                                       
62: R38         Right to Use Assets and Lease Liability - (Details  HTML     65K 
                Narrative) (10-K)                                                
55: R39         Right to Use Assets and Lease Liability - Schedule  HTML     28K 
                of Right Use of Assets (Details)                                 
71: R40         Right to Use Assets and Lease Liability - Schedule  HTML     33K 
                of Lease Liability (Details)                                     
44: R41         Right to Use Assets and Lease Liability - Schedule  HTML     27K 
                of Lease Cost (Details)                                          
25: R42         Accrued Interest - Related Party (Details           HTML     45K 
                Narrative)                                                       
30: R43         Accrued Interest - Related Party (Details           HTML     45K 
                Narrative) (10-K)                                                
70: R44         Note Payable (Details Narrative)                    HTML     41K 
43: R45         Note Payable (Details Narrative) (10-K)             HTML     41K 
24: R46         Stockholders' Deficit (Details Narrative)           HTML    186K 
29: R47         Stockholders' Deficit (Details Narrative) (10-K)    HTML    179K 
69: R48         Stockholders' Deficit - Schedule of Option          HTML     86K 
                Assumption (Details)                                             
45: R49         Stockholders' Deficit - Schedule of Warrants        HTML     52K 
                Activity (Details)                                               
46: R50         Stockholders' Deficit - Schedule of Warrants        HTML     59K 
                Outstanding (Details)                                            
56: R51         Stockholders' Deficit - Schedule of Options         HTML     31K 
                Outstanding (Details)                                            
33: R52         Commitments and Contingencies (Details Narrative)   HTML    355K 
16: R53         Commitments and Contingencies (Details Narrative)   HTML    311K 
                (10-K)                                                           
47: R54         Related Party Transactions (Details Narrative)      HTML    272K 
57: R55         Related Party Transactions (Details Narrative)      HTML    293K 
                (10-K)                                                           
34: R56         Subsequent Events (Details Narrative) (10-K)        HTML     35K 
65: XML         IDEA XML File -- Filing Summary                      XML    128K 
28: EXCEL       IDEA Workbook of Financial Reports                  XLSX     95K 
 7: EX-101.INS  XBRL Instance -- kblb-20200331                       XML   2.05M 
 9: EX-101.CAL  XBRL Calculations -- kblb-20200331_cal               XML    133K 
10: EX-101.DEF  XBRL Definitions -- kblb-20200331_def                XML    814K 
11: EX-101.LAB  XBRL Labels -- kblb-20200331_lab                     XML    909K 
12: EX-101.PRE  XBRL Presentations -- kblb-20200331_pre              XML    959K 
 8: EX-101.SCH  XBRL Schema -- kblb-20200331                         XSD    178K 
52: ZIP         XBRL Zipped Folder -- 0001493152-20-010402-xbrl      Zip    146K

‘EX-101.CAL’ — XBRL Calculations — kblb-20200331_cal

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://kraiglabs.com/role/DocumentEntityInformation" xlink:href="kblb-20200331.xsd#DocumentEntityInformation" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/BalanceSheets" xlink:href="kblb-20200331.xsd#BalanceSheets" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/BalanceSheetsParenthetical" xlink:href="kblb-20200331.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StatementsOfOperations" xlink:href="kblb-20200331.xsd#StatementsOfOperations" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StatementOfChangesInStockholdersDeficit" xlink:href="kblb-20200331.xsd#StatementOfChangesInStockholdersDeficit" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StatementOfChangesInStockholdersDeficitParenthetical" xlink:href="kblb-20200331.xsd#StatementOfChangesInStockholdersDeficitParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StatementsOfCashFlows" xlink:href="kblb-20200331.xsd#StatementsOfCashFlows" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganization" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/GoingConcern" xlink:href="kblb-20200331.xsd#GoingConcern" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/Equipment" xlink:href="kblb-20200331.xsd#Equipment" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability" xlink:href="kblb-20200331.xsd#RightToUseAssetsAndLeaseLiability" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/AccruedInterest-RelatedParty" xlink:href="kblb-20200331.xsd#AccruedInterest-RelatedParty" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/NotePayable" xlink:href="kblb-20200331.xsd#NotePayable" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StockholdersDeficit" xlink:href="kblb-20200331.xsd#StockholdersDeficit" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/CommitmentsAndContingencies" xlink:href="kblb-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RelatedPartyTransactions" xlink:href="kblb-20200331.xsd#RelatedPartyTransactions" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SubsequentEvents" xlink:href="kblb-20200331.xsd#SubsequentEvents" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationPolicies" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganizationPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationTables" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganizationTables" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/EquipmentTables" xlink:href="kblb-20200331.xsd#EquipmentTables" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiabilityTables" xlink:href="kblb-20200331.xsd#RightToUseAssetsAndLeaseLiabilityTables" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StockholdersDeficitTables" xlink:href="kblb-20200331.xsd#StockholdersDeficitTables" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationDetailsNarrative" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganizationDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganizationDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetailsParenthetical" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetailsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-kParenthetical" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-kParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfComponentsOfDeferredIncomeTaxesDetails10-k" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfComponentsOfDeferredIncomeTaxesDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfFairValueOfFinancialInstrumentsDetails" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfFairValueOfFinancialInstrumentsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfConcentrationOfCreditRiskDetails10-k" xlink:href="kblb-20200331.xsd#SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfConcentrationOfCreditRiskDetails10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/GoingConcernDetailsNarrative" xlink:href="kblb-20200331.xsd#GoingConcernDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/GoingConcernDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#GoingConcernDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/EquipmentDetailsNarrative" xlink:href="kblb-20200331.xsd#EquipmentDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/EquipmentDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#EquipmentDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/Equipment-ScheduleOfPropertyAndEquipmentDetails" xlink:href="kblb-20200331.xsd#Equipment-ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-DetailsNarrative" xlink:href="kblb-20200331.xsd#RightToUseAssetsAndLeaseLiability-DetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-DetailsNarrative10-k" xlink:href="kblb-20200331.xsd#RightToUseAssetsAndLeaseLiability-DetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-ScheduleOfRightUseOfAssetsDetails" xlink:href="kblb-20200331.xsd#RightToUseAssetsAndLeaseLiability-ScheduleOfRightUseOfAssetsDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-ScheduleOfLeaseLiabilityDetails" xlink:href="kblb-20200331.xsd#RightToUseAssetsAndLeaseLiability-ScheduleOfLeaseLiabilityDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-ScheduleOfLeaseCostDetails" xlink:href="kblb-20200331.xsd#RightToUseAssetsAndLeaseLiability-ScheduleOfLeaseCostDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/AccruedInterest-RelatedPartyDetailsNarrative" xlink:href="kblb-20200331.xsd#AccruedInterest-RelatedPartyDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/AccruedInterest-RelatedPartyDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#AccruedInterest-RelatedPartyDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/NotePayableDetailsNarrative" xlink:href="kblb-20200331.xsd#NotePayableDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/NotePayableDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#NotePayableDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StockholdersDeficitDetailsNarrative" xlink:href="kblb-20200331.xsd#StockholdersDeficitDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StockholdersDeficitDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#StockholdersDeficitDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StockholdersDeficit-ScheduleOfOptionAssumptionDetails" xlink:href="kblb-20200331.xsd#StockholdersDeficit-ScheduleOfOptionAssumptionDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StockholdersDeficit-ScheduleOfWarrantsActivityDetails" xlink:href="kblb-20200331.xsd#StockholdersDeficit-ScheduleOfWarrantsActivityDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StockholdersDeficit-ScheduleOfWarrantsOutstandingDetails" xlink:href="kblb-20200331.xsd#StockholdersDeficit-ScheduleOfWarrantsOutstandingDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/StockholdersDeficit-ScheduleOfOptionsOutstandingDetails" xlink:href="kblb-20200331.xsd#StockholdersDeficit-ScheduleOfOptionsOutstandingDetails" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="kblb-20200331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/CommitmentsAndContingenciesDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#CommitmentsAndContingenciesDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="kblb-20200331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/RelatedPartyTransactionsDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#RelatedPartyTransactionsDetailsNarrative10-k" xlink:type="simple"/>

<link:roleRef roleURI="http://kraiglabs.com/role/SubsequentEventsDetailsNarrative10-k" xlink:href="kblb-20200331.xsd#SubsequentEventsDetailsNarrative10-k" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/DocumentEntityInformation" xlink:title="00000001 - Document - Document Entity Information"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent"/>

<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="kblb-20200331.xsd#KBLB_CommonStockIssuable" xlink:label="loc_KBLBCommonStockIssuable"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_KBLBCommonStockIssuable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="kblb-20200331.xsd#KBLB_RentRelatedParty" xlink:label="loc_KBLBRentRelatedParty"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_KBLBRentRelatedParty" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StatementOfChangesInStockholdersDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders Deficit"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StatementOfChangesInStockholdersDeficitParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statement of Changes in Stockholders Deficit (Parenthetical)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="kblb-20200331.xsd#KBLB_ImputedInterestRelatedParty" xlink:label="loc_KBLBImputedInterestRelatedParty"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KBLBImputedInterestRelatedParty" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="kblb-20200331.xsd#KBLB_FairValueOfOptionsIssuedForServices" xlink:label="loc_KBLBFairValueOfOptionsIssuedForServices"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KBLBFairValueOfOptionsIssuedForServices" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense"/>

<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="kblb-20200331.xsd#KBLB_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:label="loc_KBLBIncreaseDecreaseInOperatingLeaseRightofuseAssets"/>

<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KBLBIncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade"/>

<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilities"/>

<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilities" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent"/>

<link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" weight="1"/>

<link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="kblb-20200331.xsd#KBLB_WarrantsIssuedcancelledToConsultants" xlink:label="loc_KBLBWarrantsIssuedcancelledToConsultants"/>

<link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_KBLBWarrantsIssuedcancelledToConsultants" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable"/>

<link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies and Organization"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/GoingConcern" xlink:title="00000009 - Disclosure - Going Concern"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/Equipment" xlink:title="00000010 - Disclosure - Equipment"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability" xlink:title="00000011 - Disclosure - Right to Use Assets and Lease Liability"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/AccruedInterest-RelatedParty" xlink:title="00000012 - Disclosure - Accrued Interest - Related Party"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/NotePayable" xlink:title="00000013 - Disclosure - Note Payable"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StockholdersDeficit" xlink:title="00000014 - Disclosure - Stockholders' Deficit"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RelatedPartyTransactions" xlink:title="00000016 - Disclosure - Related Party Transactions"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationPolicies" xlink:title="00000018 - Disclosure - Summary of Significant Accounting Policies and Organization (Policies)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationTables" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies and Organization (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/EquipmentTables" xlink:title="00000020 - Disclosure - Equipment (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiabilityTables" xlink:title="00000021 - Disclosure - Right to Use Assets and Lease Liability (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StockholdersDeficitTables" xlink:title="00000022 - Disclosure - Stockholders' Deficit (Tables)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationDetailsNarrative" xlink:title="00000023 - Disclosure - Summary of Significant Accounting Policies and Organization (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationDetailsNarrative10-k" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies and Organization (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Antidilutive Securities of Earnings Per Share (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetailsParenthetical" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Antidilutive Securities of Earnings Per Share (Details) (Parenthetical)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-k" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails10-kParenthetical" xlink:title="00000028 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Deferred Tax Assets and Liabilities (Details) (10-K) (Parenthetical)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfComponentsOfDeferredIncomeTaxesDetails10-k" xlink:title="00000029 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Components of Deferred Income Taxes (Details) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfFairValueOfFinancialInstrumentsDetails" xlink:title="00000030 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Fair Value of Financial Instruments (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfConcentrationOfCreditRiskDetails10-k" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Concentration of Credit Risk (Details) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/GoingConcernDetailsNarrative" xlink:title="00000032 - Disclosure - Going Concern (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/GoingConcernDetailsNarrative10-k" xlink:title="00000033 - Disclosure - Going Concern (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/EquipmentDetailsNarrative" xlink:title="00000034 - Disclosure - Equipment (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/EquipmentDetailsNarrative10-k" xlink:title="00000035 - Disclosure - Equipment (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/Equipment-ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000036 - Disclosure - Equipment - Schedule of Property and Equipment (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-DetailsNarrative" xlink:title="00000037 - Disclosure - Right to Use Assets and Lease Liability - (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-DetailsNarrative10-k" xlink:title="00000038 - Disclosure - Right to Use Assets and Lease Liability - (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-ScheduleOfRightUseOfAssetsDetails" xlink:title="00000039 - Disclosure - Right to Use Assets and Lease Liability - Schedule of Right Use of Assets (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-ScheduleOfLeaseLiabilityDetails" xlink:title="00000040 - Disclosure - Right to Use Assets and Lease Liability - Schedule of Lease Liability (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RightToUseAssetsAndLeaseLiability-ScheduleOfLeaseCostDetails" xlink:title="00000041 - Disclosure - Right to Use Assets and Lease Liability - Schedule of Lease Cost (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/AccruedInterest-RelatedPartyDetailsNarrative" xlink:title="00000042 - Disclosure - Accrued Interest - Related Party (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/AccruedInterest-RelatedPartyDetailsNarrative10-k" xlink:title="00000043 - Disclosure - Accrued Interest - Related Party (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/NotePayableDetailsNarrative" xlink:title="00000044 - Disclosure - Note Payable (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/NotePayableDetailsNarrative10-k" xlink:title="00000045 - Disclosure - Note Payable (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StockholdersDeficitDetailsNarrative" xlink:title="00000046 - Disclosure - Stockholders' Deficit (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StockholdersDeficitDetailsNarrative10-k" xlink:title="00000047 - Disclosure - Stockholders' Deficit (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StockholdersDeficit-ScheduleOfOptionAssumptionDetails" xlink:title="00000048 - Disclosure - Stockholders' Deficit - Schedule of Option Assumption (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StockholdersDeficit-ScheduleOfWarrantsActivityDetails" xlink:title="00000049 - Disclosure - Stockholders' Deficit - Schedule of Warrants Activity (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StockholdersDeficit-ScheduleOfWarrantsOutstandingDetails" xlink:title="00000050 - Disclosure - Stockholders' Deficit - Schedule of Warrants Outstanding (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/StockholdersDeficit-ScheduleOfOptionsOutstandingDetails" xlink:title="00000051 - Disclosure - Stockholders' Deficit - Schedule of Options Outstanding (Details)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000052 - Disclosure - Commitments and Contingencies (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/CommitmentsAndContingenciesDetailsNarrative10-k" xlink:title="00000053 - Disclosure - Commitments and Contingencies (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000054 - Disclosure - Related Party Transactions (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/RelatedPartyTransactionsDetailsNarrative10-k" xlink:title="00000055 - Disclosure - Related Party Transactions (Details Narrative) (10-K)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://kraiglabs.com/role/SubsequentEventsDetailsNarrative10-k" xlink:title="00000056 - Disclosure - Subsequent Events (Details Narrative) (10-K)"/>

</link:linkbase>

22 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/22/23  Kraig Biocraft Laboratories, Inc. S-1/A                 67:13M                                    M2 Compliance LLC/FA
 9/01/23  Kraig Biocraft Laboratories, Inc. POS AM                67:13M                                    M2 Compliance LLC/FA
 9/01/23  Kraig Biocraft Laboratories, Inc. S-1/A                 67:13M                                    M2 Compliance LLC/FA
 6/06/23  Kraig Biocraft Laboratories, Inc. S-1/A                 66:13M                                    M2 Compliance LLC/FA
 5/09/23  Kraig Biocraft Laboratories, Inc. S-1/A                  1:2.2M                                   M2 Compliance LLC/FA
 4/27/23  Kraig Biocraft Laboratories, Inc. S-1/A                  1:2.2M                                   M2 Compliance LLC/FA
 4/14/23  Kraig Biocraft Laboratories, Inc. S-1/A                 65:9.9M                                   M2 Compliance LLC/FA
 4/14/23  Kraig Biocraft Laboratories, Inc. POS AM                65:9.1M                                   M2 Compliance LLC/FA
12/01/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:14M                                    M2 Compliance LLC/FA
 5/25/22  Kraig Biocraft Laboratories, Inc. S-1/A                 64:12M                                    M2 Compliance LLC/FA
 4/14/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:10M                                    M2 Compliance LLC/FA
 3/23/22  Kraig Biocraft Laboratories, Inc. S-1/A                 65:9.7M                                   M2 Compliance LLC/FA
 2/10/22  Kraig Biocraft Laboratories, Inc. S-1                   67:13M                                    M2 Compliance LLC/FA
12/03/21  Kraig Biocraft Laboratories, Inc. S-1/A                 64:13M                                    M2 Compliance LLC/FA
 8/25/21  Kraig Biocraft Laboratories, Inc. S-1/A                 63:12M                                    M2 Compliance LLC/FA
 5/26/21  Kraig Biocraft Laboratories, Inc. S-1/A                 86:9.3M                                   M2 Compliance LLC/FA
 4/15/21  Kraig Biocraft Laboratories, Inc. S-1/A                  1:74K                                    M2 Compliance LLC/FA
 4/14/21  Kraig Biocraft Laboratories, Inc. S-1/A                  2:161K                                   M2 Compliance LLC/FA
 4/05/21  Kraig Biocraft Laboratories, Inc. S-1                   63:6M                                     M2 Compliance LLC/FA
 2/18/21  Kraig Biocraft Laboratories, Inc. S-1/A                 78:9.1M                                   M2 Compliance LLC/FA
 2/08/21  Kraig Biocraft Laboratories, Inc. S-1/A                 78:9.1M                                   M2 Compliance LLC/FA
 8/24/20  Kraig Biocraft Laboratories, Inc. S-1/A                 68:7.8M                                   M2 Compliance LLC/FA

↑Top

Filing Submission 0001493152-20-010402 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Kraig Biocraft Laboratories, Inc – ‘S-1’ on 6/2/20 – ‘EX-101.CAL’

On: Tuesday, 6/2/20, at 4:47pm ET · Accession #: 1493152-20-10402 · File #: 333-238883

Registration Statement (General Form) — Form S-1Filing Table of Contents

‘EX-101.CAL’ — XBRL Calculations — kblb-20200331_cal

This Exhibit is an XBRL XML File.

22 Subsequent Filings that Reference this Filing

Registration Statement (General Form) — Form S-1
Filing Table of Contents